Technology
Choose a subcategory:
Protalix Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Di
Factors that might cause material differences include, among others: risks relating to the review process of the FDA, the European Medicines Agency ( EMA), other foreign regulatory bodies and other governmental regulatory bodies, including
Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements, include, but are not limited to, the risks and uncertainties inherent in clinical trials, product deve
( " Apricus Bio" or the " Company") today announced that it intends to offer units consisting of shares of common stock and warrants in an underwritten public offering.
Financial Data Condensed Consolidated Financial Data ( In thousands, except per-share data) Unaudited Three months ended Year ended December 31, December 31, 2011 2010 2011 2010 Results of Operations Revenues $ 23,690 $ 18,817 $ 81,881 $ 75
About Amicus Therapeutics Amicus Therapeutics is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases.
StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery.
WILMINGTON, Mass., Feb. 8, 2012 ( GLOBE NEWSWIRE)- DUSA Pharmaceuticals, Inc. ( R), a dermatology company that is developing and marketing Levulan ( R) Photodynamic Therapy ( PDT), announced that Bob Doman, President and Chief Executive Off
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS ( UNAUDITED) Three months ended Year ended December 31, December 31, 2011 2010 2011 2010 Revenues $ 14,089,053 $ 100,287 $ 14,762,580 $ 15,999,565 Operating expenses: Research and development
New York Stem Cell Summit 2012 Date: February 21, 2012 Venue: Bridgewaters, New York, New York Presenters: Dr. Robin L. Smith, Chairman and CEO of NeoStem will present NeoStem's corporate presentation at 1: 47 PM and Robert A. Preti, PhD, P
VICAL INCORPORATED Selected Condensed Financial Information ( Unaudited) Three Months Ended Twelve Months Ended Statements of Operations Dec. 31, Dec. 31, ( in thousands, except per share amounts) 2011 2010 2011 2010 Revenues: Contract and
Factors that may cause the Company's actual results to differ materially from those in the forward-looking statements include the Company's inability to integrate the business acquired from AHN, the failure of the business acquired from AHN
Intermolecular, Inc. Condensed Consolidated Statements of Operations ( In thousands, except per share amounts, Unaudited) Three Months Ended Year Ended December December 31, 31, 2011 2010 2011 2010 Revenue: Collaborative development program